https://www.fool.com/investing/general/2014/06/11/is-medtronic-a-buy-what-analyst-day-revealed.aspx
https://www.fool.com/investing/general/2014/05/14/healthcare-buyout-mania-now-what.aspx
https://www.fool.com/investing/general/2014/04/07/can-express-scripts-holding-co-beat-expectations-a.aspx
https://www.fool.com/investing/general/2014/04/15/this-forgotten-pharma-could-be-a-hit-for-your-port.aspx
https://www.fool.com/investing/2016/11/22/will-this-franchise-lead-celgene-to-over-20-billio.aspx
https://www.fool.com/investing/general/2014/05/29/why-stryker-should-buy-smith-nephew.aspx
https://www.fool.com/investing/general/2014/07/01/time-to-buy-a-stumbling-unitedhealth-group-inc.aspx
https://www.fool.com/investing/general/2014/06/20/will-shires-journey-end-in-a-ring.aspx
https://www.fool.com/investing/general/2014/04/16/st-jude-medical-inc-in-line-is-just-not-good-enoug.aspx
https://www.fool.com/investing/general/2014/04/09/can-perrigo-company-plc-continue-its-bull-run.aspx
https://www.fool.com/investing/general/2014/07/20/why-google-could-transform-how-we-see.aspx
https://www.fool.com/investing/general/2014/06/30/mannkind-stock-afrezza-approved-at-last-but-will-s.aspx
https://www.fool.com/investing/general/2014/07/21/allergan-stock-earnings-good-enough-to-fight-off-v.aspx
https://www.fool.com/investing/general/2014/04/24/13-billion-bold-play-zimmer-holdings-incs-purchase.aspx
https://www.fool.com/investing/general/2014/04/11/whats-behind-intuitive-surgical-incs-revenue-miss.aspx
https://www.fool.com/investing/general/2014/03/27/is-teva-pharmaceutical-industries-ltd-turning-a-co.aspx
https://www.fool.com/investing/2016/10/31/celgene-boldly-targeting-6-billion-or-more-in-new.aspx
https://www.fool.com/investing/general/2014/07/24/keep-calm-and-carry-on-roche-stock.aspx
https://www.fool.com/investing/general/2014/07/18/abbvie-inc-wins-the-shire.aspx
https://www.fool.com/investing/general/2014/06/24/a-big-step-forward-for-vertex-pharmaceuticals-inc.aspx
https://www.fool.com/investing/general/2014/06/10/will-mercks-bold-hepatitis-c-play-pay-off.aspx
https://www.fool.com/investing/general/2014/05/11/valeant-pharmaceuticalss-earnings-take-a-back-seat.aspx
https://www.fool.com/investing/general/2014/07/18/heavy-static-at-danaher-corporation.aspx
https://www.fool.com/investing/general/2014/04/21/pfizer-inc-rebuffed-is-astrazeneca-plc-worth-anoth.aspx
https://www.fool.com/investing/general/2014/07/16/should-roche-buy-exelixis.aspx
https://www.fool.com/investing/general/2014/05/29/why-valeants-offer-is-unlikely-to-move-the-needle.aspx
https://www.fool.com/investing/general/2014/04/28/do-disappointing-earnings-create-a-good-buying-opp.aspx
https://www.fool.com/investing/general/2014/05/06/does-strykers-skid-offer-a-buying-opportunity.aspx
https://www.fool.com/investing/general/2014/04/17/even-with-a-change-at-the-top-danaher-corporation.aspx
https://www.fool.com/investing/general/2014/05/23/can-novartis-ag-maintain-its-momentum.aspx
https://www.fool.com/investing/general/2014/05/16/asco-2014-making-and-breaking-cancer-drugs.aspx
https://www.fool.com/investing/general/2014/03/28/exelixis-incs-comet-fails-to-dazzle.aspx
https://www.fool.com/investing/general/2014/03/31/what-you-need-to-know-about-the-agilent-technologi.aspx
https://www.fool.com/investing/general/2014/05/13/alnylam-pharmaceuticals-inc-managing-multiple-iron.aspx
https://www.fool.com/investing/general/2014/07/17/forget-earnings-catalysts-incoming-for-novartis-st.aspx
https://www.fool.com/investing/general/2014/06/16/medtronic-inc-changes-the-game.aspx
https://www.fool.com/investing/general/2014/07/15/can-roche-find-rare-success-in-alzheimers.aspx
https://www.fool.com/investing/general/2014/07/22/is-alkermes-plc-stock-undervalued.aspx
https://www.fool.com/investing/general/2014/06/15/will-apples-new-health-care-push-pay-off.aspx
https://www.fool.com/investing/general/2014/07/24/with-baseband-finished-a-higher-margin-broadcom-co.aspx
https://www.fool.com/investing/general/2014/07/18/stryker-corporation-stock-coming-through-with-grow.aspx
https://www.fool.com/investing/general/2014/07/03/obamacare-and-medicare-advantage-how-wellpoint-cou.aspx
https://www.fool.com/investing/general/2014/04/22/is-this-a-good-deal-for-novartis-ag-and-glaxosmith.aspx
https://www.fool.com/investing/general/2014/04/01/can-this-drive-growth-for-amarin-corporation-plc.aspx
https://www.fool.com/investing/general/2014/04/07/pfizer-incs-palbociclib-delivers-the-goods.aspx
https://www.fool.com/investing/general/2014/06/25/a-smart-move-for-endo-international.aspx
https://www.fool.com/investing/general/2014/06/17/is-roches-dividend-in-danger.aspx
https://www.fool.com/investing/general/2014/04/15/how-much-has-merck-shaken-up-the-hepatitis-c-race.aspx
https://www.fool.com/investing/general/2014/07/14/abbott-and-mylan-winners-and-winners.aspx
https://www.fool.com/investing/general/2014/06/02/3-reasons-to-like-zoetis.aspx
https://www.fool.com/investing/general/2014/04/24/execution-key-to-cameron-international-corp-unlock.aspx
https://www.fool.com/investing/general/2014/07/15/johnson-johnson-ups-the-dosage.aspx
https://www.fool.com/investing/general/2014/05/06/why-3m-cos-performance-is-better-than-it-looks.aspx
https://www.fool.com/investing/general/2014/07/01/up-8-does-cooper-companies-incs-buyout-make-sense.aspx
https://www.fool.com/investing/general/2014/07/13/the-truth-behind-obamacares-job-killing-tax.aspx
https://www.fool.com/investing/general/2014/07/25/boston-scientific-stock-down-slightly-on-earnings.aspx
https://www.fool.com/investing/general/2014/07/16/st-jude-medical-inc-still-feeling-the-love.aspx
https://www.fool.com/investing/general/2014/04/14/edwards-lifesciences-corp-scores-a-potentially-maj.aspx
https://www.fool.com/investing/general/2014/05/27/johnson-johnson-focusing-on-quality-over-quantity.aspx
https://www.fool.com/investing/general/2014/05/22/good-news-at-boston-scientific-whats-next.aspx
https://www.fool.com/investing/general/2014/06/27/auxilium-pharmaceuticals-inc-joins-the-buyout-bona.aspx
https://www.fool.com/investing/general/2014/04/04/can-davita-healthcare-partners-incs-run-last.aspx
https://www.fool.com/investing/general/2014/07/14/can-anything-derail-salix-pharmaceuticals.aspx
https://www.fool.com/investing/general/2014/04/03/monsanto-companys-balanced-growth-proves-stronger.aspx
https://www.fool.com/investing/general/2014/07/18/why-the-market-is-wrong-about-baxter-stock.aspx
https://www.fool.com/investing/general/2014/07/17/jpmorgan-chase-cos-broad-based-beat-restores-some.aspx
https://www.fool.com/investing/general/2014/04/30/are-boston-scientific-corporations-little-misses-p.aspx
https://www.fool.com/investing/general/2014/07/10/is-this-huge-market-slowing-down.aspx
https://www.fool.com/investing/general/2014/05/05/after-missing-earnings-is-pfizer-a-good-value.aspx
https://www.fool.com/investing/general/2014/05/01/are-investors-putting-too-much-faith-in-novo-nordi.aspx
https://www.fool.com/investing/general/2014/04/02/can-fresenius-medical-care-ag-co-get-past-medicare.aspx
https://www.fool.com/investing/general/2014/04/23/illumina-incs-seemingly-endless-victory-lap.aspx
https://www.fool.com/investing/general/2014/03/26/will-shire-plc-build-or-buy-its-future.aspx
https://www.fool.com/investing/general/2014/04/15/johnson-johnsons-earnings-report-impresses.aspx
https://www.fool.com/investing/general/2014/06/23/bostons-watchman-under-new-fda-scrutiny.aspx
https://www.fool.com/investing/general/2014/04/07/is-there-opportunity-in-the-eye-care-sector.aspx
https://www.fool.com/investing/general/2014/07/28/weatherford-international-rebuilding-trust-but-nee.aspx
https://www.fool.com/investing/general/2014/07/02/roche-holding-ltd-is-betting-billions-on-this-ne-2.aspx
https://www.fool.com/investing/general/2014/06/19/is-pfizer-putting-the-car-t-before-the-horse.aspx
https://www.fool.com/investing/general/2014/06/20/who-will-win-this-45-billion-market.aspx
https://www.fool.com/investing/general/2014/05/27/is-biogen-idec-inc-a-buy.aspx
https://www.fool.com/investing/general/2014/07/09/fleeing-taxes-salix-pharmaceuticals-moves-to-irela.aspx
https://www.fool.com/investing/general/2014/05/20/why-im-still-bullish-on-medtronic.aspx
https://www.fool.com/investing/general/2014/05/19/4th-time-not-yet-the-charm-for-pfizer.aspx
https://www.fool.com/investing/general/2014/04/28/for-forest-labs-inc-deals-are-coming-fast-and-furi.aspx
https://www.fool.com/investing/general/2014/04/08/mallinckrodt-plc-takes-a-big-swing-for-growth.aspx
https://www.fool.com/investing/general/2014/07/28/emc-corporation-is-gaining-share-but-facing-a-figh.aspx
https://www.fool.com/investing/general/2014/03/27/will-baxter-international-incs-split-unlock-shareh.aspx
https://www.fool.com/investing/general/2014/07/02/why-salix-pharmaceuticals-good-data-wasnt-great.aspx
https://www.fool.com/investing/general/2014/05/08/can-allergan-remain-independent-of-valeant.aspx
https://www.fool.com/investing/general/2014/07/16/abbott-labs-stock-earnings-why-steady-isnt-enough.aspx
https://www.fool.com/investing/general/2014/06/16/3-undervalued-amgen-growth-opportunities-to-watch.aspx
https://www.fool.com/investing/general/2014/07/14/abbvie-and-shire-close-to-the-altar-but-not-there.aspx
https://www.fool.com/investing/general/2014/04/23/can-allergan-find-an-alternative-to-valeant.aspx
https://www.fool.com/investing/general/2014/07/29/3m-delivers-again-but-mind-the-multiple.aspx
https://www.fool.com/investing/general/2014/07/23/why-the-market-is-wrong-about-intuitive-surgical-s.aspx
https://www.fool.com/investing/general/2014/04/16/abbott-labs-earnings-still-marking-time.aspx
https://www.fool.com/investing/general/2014/04/28/the-clouds-are-parting-for-weatherford-internation.aspx
https://www.fool.com/investing/general/2014/05/08/why-mercks-bayer-deal-makes-sense.aspx
https://www.fool.com/investing/general/2014/05/02/is-becton-dickinson-and-company-a-buy.aspx
